Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT

Summary

Small cell ovarian carcinomas are rare and have a very poor prognosis affecting a young population. The objective of this study is to increase the efficacy of the initial chemotherapy by providing immunotherapy and to be able to offer to more patients the possibility of benefiting from an intensification of chemotherapy, which is a major prognostic factor in this population.

Timeline

Start

2021-08-04

Primary completion

2026-06

Completion

2030-02

Drugs

Indications